What Is an Investigator Brochure (IB) in Clinical Trials?

Introduction

Every clinical investigator who enrolls a patient into a trial carries a legal and ethical obligation: they must understand the investigational product well enough to protect that patient. The document that makes this possible is the Investigator Brochure (IB). It sits at the center of some of the most consequential decisions in a trial, including whether an adverse event is classified as expected or unexpected and whether that classification triggers a regulatory safety report.

Yet the IB is frequently underestimated. Teams treat it as a background document, updated reluctantly and often late. The MHRA's GCP inspectorate has stated explicitly that, since 2019, it has identified critical findings related to Reference Safety Information (RSI) non-compliance at eight organizations in a single inspection pilot, with unreported Suspected Unexpected Serious Adverse Reactions (SUSARs) and missing risk mitigation measures directly traceable to incorrect IB application ^[1]. These are not minor administrative failures; they have patient safety consequences.

This article covers what the IB is, what it must contain, how it functions as a live regulatory instrument, and what the January 2025 finalization of ICH E6(R3) ^[2] means for sponsors and medical writers.

Why the Investigator Brochure Matters

ICH E6(R3) Appendix A defines the IB as "a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human participants" ^[2]. Its purpose, stated directly in the guideline, is to "provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for and their compliance with many key features of the protocol, such as the dose, dose frequency/interval, methods of administration and safety monitoring procedures" ^[2].

Under U.S. federal regulations, the requirement to provide an IB to each participating investigator before the trial begins is established at 21 CFR 312.55(a), which states: "Before the investigation begins, a sponsor (other than a sponsor-investigator) shall give each participating clinical investigator an investigator brochure containing the information described in § 312.23(a)(5)" ^[3]. ICH member regions implement IB requirements through their own regulatory mechanisms and guidance. As of November 2025, ICH comprises 25 members and 41 observers ^[4], meaning the IB framework now shapes regulatory expectations across most major drug development markets globally.

The IB's operational importance rests on three distinct functions. First, it gives investigators the clinical and pharmacological context needed to understand the protocol's rationale rather than simply following it by instruction. Second, it defines what adverse reactions are considered "expected" through the Reference Safety Information (RSI) section. Under EU Clinical Trials Regulation 536/2014 Article 42, sponsors must report SUSARs to EudraVigilance within 7 calendar days for fatal or life-threatening events and within 15 calendar days for non-fatal, non-life-threatening events ^[5]. Whether a serious, causally suspected adverse reaction qualifies as a SUSAR turns on whether it is "unexpected"; meaning not listed in the RSI at the observed specificity or severity. The RSI is therefore the operative document for that determination. Third, the IB is a required submission to IRBs and IECs: ICH E6(R3) section 2.4.3 requires that "as part of the investigator's/institution's or sponsor's submission to the IRB/IEC, a current copy of the Investigator's Brochure or basic product information brochure should be provided" ^[2].

The relationship between IB accuracy and patient safety is therefore direct and immediate. A poorly maintained IB distorts adverse event classification in both directions: over-listing expected reactions suppresses legitimate safety signals that should reach regulators, while failing to maintain the RSI current means investigators and ethics committees do not receive important new information in time.

What Must an Investigator Brochure Contain?

The Regulatory Floor: 21 CFR 312.23(a)(5)

Under U.S. law, the IB submitted as part of an IND application must contain five categories of information ^[6]:

1. 1A brief description of the drug substance and formulation, including the structural formula if known.
2. 2A summary of pharmacological and toxicological effects in animals and, to the extent known, in humans.
3. 3A summary of pharmacokinetics and biological disposition in animals and, if known, in humans.
4. 4A summary of information relating to safety and effectiveness in humans from prior clinical studies.
5. 5A description of possible risks and side effects to be anticipated based on prior experience with the drug or drugs in the same class, and of precautions or special monitoring to be done as part of the investigational use.

These five elements are the legal minimum for U.S. IND submissions ^[6]. ICH E6(R3) Appendix A specifies a considerably fuller structure that many regulators and review boards now use or expect alignment with.

The International Standard: ICH E6(R3) Appendix A

ICH E6(R3), adopted on January 6, 2025 ^[2], organizes the IB content into the following sections:

Title Page. The product's research number, generic and trade names if applicable, the sponsor's name, the edition number, the release date, and a confidentiality statement ^[2].

Summary. A concise overview of the most significant chemical, pharmacological, toxicological, and clinical information relevant to the current stage of development. The guideline describes this section as an introduction for the reader, not a substitute for the full document ^[2].

Introduction. The drug's chemical name, pharmacological class, rationale for the research program, and the anticipated indication, including the mechanism of action where known ^[2].

Physical, Chemical, and Pharmaceutical Properties and Formulation. A description of the investigational product's composition, physicochemical properties, and formulation. This section provides investigators with the information needed to store, handle, and administer the product safely ^[2].

Nonclinical Studies. Summaries of pharmacology, pharmacokinetics, and toxicology findings from animal studies. Cross-species differences that could bear on the interpretation of human safety data should be discussed ^[2].

Effects in Humans. All available clinical data, covering pharmacokinetics, safety, and efficacy findings from completed and ongoing studies, along with any marketed-use experience. The guideline notes that tabular summaries across multiple studies can be especially useful for demonstrating outcomes in different patient populations or indications ^[2].

Summary of Data and Guidance for the Investigator. This is the document's operational core. ICH E6(R3) Appendix A states its purpose is to give the investigator "a clear understanding of the possible risks and adverse reactions, and of the specific tests, observations, and precautions that may be needed for a clinical trial," based on all available physical, chemical, pharmaceutical, pharmacological, toxicological, and clinical information ^[2]. Critically, this section should contain or clearly reference the RSI; "a list of adverse reactions, including information on their frequency and nature," used to determine SUSAR expectedness ^[2].

The authoring standard matters as much as the content. ICH E6(R3) specifies that a medically qualified person should generally participate in editing the IB, and that each discipline contributing data should review and approve its respective content ^[2]. The guideline further states that the IB should be written concisely, simply, objectively, and without promotional framing ^[2].

How the IB Functions as a Living Document

The IB is not written once at study initiation and filed. It is a living document that must track the evolving evidence base for the investigational product throughout the development program.

ICH E6(R3) Appendix A requires that the IB "be reviewed at least annually and revised as necessary," and notes that "more frequent revision may be appropriate depending on the stage of development and the generation of relevant new information" ^[2]. Relevant new information is defined as information that substantially changes what is known about the product's characteristics, especially with respect to safety ^[2].

U.S. regulations reinforce this at 21 CFR 312.33(d), which requires that if the IB has been revised during the preceding year, the sponsor must include a description of the revision and a copy of the updated brochure in the annual IND report, due within 60 days of the IND anniversary date ^[7].

The annual review requirement is not a formality. An IB that lags behind the evidence base directly impairs the RSI, which in turn affects SUSAR classification on every trial running under that product. Sponsors who allow the IB to become stale risk under-reporting safety events to regulators and failing to communicate critical safety information to investigators as required by 21 CFR 312.55(b) ^[3].

When new safety information is too urgent to wait for the annual revision cycle, sponsors have two recognized approaches. The IB can be amended immediately and the revised version distributed to all investigators. Alternatively, sponsors sometimes issue a formal addendum that supplements the current version pending the next full revision. The MHRA's inspectorate has flagged non-compliance where RSI updates were delayed following regulatory approval of amendments, and where the RSI version applied to an adverse event was not the version in effect at the date of the event's onset, but a later version ^[1]. Both errors result in incorrect expectedness assessments.

Who Is Responsible?

The sponsor bears primary responsibility for preparing, maintaining, and distributing the IB. ICH E6(R3) Appendix A states that "generally, the sponsor is responsible for ensuring that an up-to-date IB is developed" ^[2]. For investigator-initiated trials, the sponsor-investigator should first check whether a brochure is available from the product license or marketing authorization holder before developing one independently ^[2].

In practice, IB authorship is a multidisciplinary undertaking involving regulatory affairs, pharmacology, toxicology, clinical teams, and medical writers, all working under the oversight of a medically qualified individual ^[2]. For sponsor-investigator INDs at academic institutions, development from initiation through clinical, manufacturing, and nonclinical review can represent a substantial planning commitment; academic clinical trial units routinely advise principal investigators to account for this when scheduling IND submissions.

Operational Implications: What Can Go Wrong

The IB's functional role in SUSAR classification makes errors in its content operationally dangerous in a way that distinguishes it from most other trial documents. A poorly written protocol creates operational confusion. A poorly maintained IB creates safety reporting errors.

The MHRA GCP inspectorate documented specific non-compliance patterns in its RSI Part III post, based on findings from a focused inspection pilot. Since January 2019, the MHRA identified critical RSI findings at eight organizations within that pilot ^[1]. The most consequential finding category was unreported SUSARs: cases where events were incorrectly assessed as expected against an outdated or misapplied RSI, and therefore never reported. The inspectorate also identified delayed IB update implementation after regulatory approval of amendments; meaning the RSI change had been approved but not yet distributed to investigators or applied to adverse event assessments ^[1].

A related operational challenge is what practitioners in regulatory medical writing sometimes call "document bloat": successive IB versions that append new data without restructuring or synthesizing the existing content. The result is a document that grows in length while becoming progressively harder to navigate, particularly for the summary and RSI sections that investigators and pharmacovigilance staff consult most urgently. ICH E6(R3) addresses this implicitly by requiring each revision to genuinely reflect the current state of knowledge rather than function as a cumulative appendage to an earlier draft ^[2].

Inconsistency between the IB and other trial documents is a separate and persistent problem. When the RSI conflicts with adverse event classification criteria in the protocol, or when the IB's pharmacology summary does not align with the protocol's dose-rationale section, investigators receive contradictory guidance. A 2022 analysis of joint FDA-EMA GCP inspections published in the Journal of Clinical and Translational Science found that documentation deficiencies were among the most common findings across both agency inspection programs, with high concordance between the two agencies on documentation-related citations ^[8]. Inconsistencies within the trial master file; including between key documents; fall squarely within this finding category.

Regulatory and Documentation Considerations Under ICH E6(R3)

The January 2025 finalization of ICH E6(R3) did not redesign the IB's required content, but it restructured the broader GCP framework in ways that carry direct implications for how the IB is positioned and maintained.

ICH E6(R3) reorganizes the guideline into a core Principles section and modular appendices ^[2]. The IB is addressed in Appendix A of the finalized text, which preserves the content framework while aligning terminology with the guideline's revised principles; including the replacement of "subject" with "trial participant" throughout ^[2].

Three regulatory implementation timelines are relevant for teams developing IBs in 2026. The EMA made ICH E6(R3) Principles and Annex 1 effective on July 23, 2025 ^[9]. The FDA issued final guidance adopting the guideline on September 8, 2025; this guidance reflects current FDA thinking but does not itself replace the enforceable requirements in 21 CFR Parts 50, 56, and 312 ^[10]. The MHRA published UK-specific annotations to ICH E6(R3) on January 12, 2026, with the guideline coming into force in the UK on April 28, 2026 alongside the amended Medicines for Human Use (Clinical Trials) Regulations ^[11]. Annex 2, which will address non-traditional trial designs including decentralized and pragmatic elements, remained a Step 2b draft as of June 2026; public consultation had closed in February 2025, but no final Step 4 text had been published on the EMA page ^[12].

For the IB specifically, three principles-level shifts in E6(R3) have downstream documentation implications. The guideline's increased emphasis on quality-by-design and proportionate, risk-based approaches means sponsors are expected to demonstrate that the RSI reflects an active, evidence-based risk assessment rather than a passive historical list of adverse events. The introduction of data governance requirements reinforces the need for documented, auditable processes covering IB version control, investigator acknowledgment of updated versions, and the date from which each RSI version is operative for expectedness assessments. And the updated glossary's terminology changes affect IB language for all trials initiated or substantially amended under E6(R3) ^[2].

AI and Automation in IB Preparation

Sponsors are exploring how AI-assisted document generation may reduce the time and burden associated with IB authorship and annual revision, particularly for cycles where the core challenge is synthesizing new clinical and nonclinical data into an existing structured document without introducing inconsistencies in the RSI.

The potential is real but bounded. An IB requires integration of heterogeneous source materials: animal study reports, clinical study reports, post-marketing pharmacovigilance summaries, and published literature, all synthesized under a defined regulatory structure. Tools that can ingest structured data from these sources and generate draft section text reduce the assembly burden for medical writers. The RSI section, however, requires expert medical judgment. The decision to classify an adverse reaction as expected for SUSAR purposes carries direct regulatory and patient safety consequences. ICH E6(R3) is clear that a medically qualified person must participate in the editing process ^[2], and automated generation cannot substitute for that judgment.

The MHRA's inspection findings on RSI misapplication ^[1] underscore this point. The errors regulators are finding are substantive classification errors made by qualified professionals working under time and organizational pressure, not mechanical formatting mistakes. The role of AI in this context is most defensible as an efficiency tool that frees qualified reviewers to spend their attention on the judgments that matter, particularly RSI construction and cross-document consistency verification.

How Kitsa Fits Into This Problem

IB preparation falls within the category of regulatory documents that are technically demanding, multidisciplinary, and revision-sensitive. KScribe, Kitsa's AI-powered document platform, is designed for exactly this class of document: those that synthesize nonclinical and clinical data under a defined regulatory structure, carry a mandatory annual revision cycle, and must maintain consistency with parallel documents like the protocol and DSUR. For teams managing multiple concurrent programs or preparing IBs on accelerated IND timelines, reducing first-draft assembly time without compromising RSI accuracy or cross-document traceability is where the practical workflow problem sits.

Key Takeaways

Frequently Asked Questions

References

You Might Also Like